Targeted therapy pralsetinib safely and effectively treats lung and thyroid cancers with RET alterations
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer. The findings for each cohort were published today in The Lancet Oncology and...
